Business
Liquidia Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per
About this update from Liquidia Corporation
[{"type":"text","content":"Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per sessionAchieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into extension trialSafety profile was consistent with known prostacyclin side effects and mostly mild to moderate in severity whether naïve to prostacyclin therapy or transitioning from a stable dose of Tyvaso MORRISVILLE, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the publication of clinical data from the completed INSPIRE study evaluating YUTREPIA™ (treprostinil) inhalation powder, formerly known as LIQ861, in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation. This publication reports clinical outcomes of PAH patients treated with YUTREPIA who were naïve to prostacyclin therapy (Naïve patients) or transitioning from nebulized Tyvaso® (Transition patients). The average length of treatment was approximately one year, with patients rolling into an open-label safety extension trial at varying times between 8 to 18 months. Observations noted in the publication include: YUTREPIA can be safely titrated using a dry powder inhaler to doses comparable to 24 breaths of Tyvaso, indicating that a wide range of therapeutic doses can be more easily administered in just a few breaths compared to nebulizersNaïve patients can safely achieve known therapeutic levels within 2 months and titrate to doses above the recommended, comparable dose range of 9-12 breath of TyvasoBoth Naïve and Transition patients maintained or improved in exploratory measures of clinical efficacy; however, the study was not designed or controlled to make definitive statements Dr. Rajeev Saggar, Chief Medical Officer at Liquidia, said: “The INSPIRE study confirms the long-term safety profile, dosing convenience, and tolerability of YUTREPIA in PAH patients. We are grateful to the efforts of the clinical investigation teams, our steering committee, and most importantly to the PAH community who participated in this study and those continuing in the open-label extension.” INSPIRE Study. The pivotal, open label INSPIRE study enrolled 121 adult PAH patients naïve to prostacyclin (n=66, Naive) and patie...